Italia markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
28,16+0,27 (+0,97%)
Alla chiusura: 04:00PM EDT
28,75 +0,59 (+2,10%)
Dopo ore: 06:07PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente27,89
Aperto27,85
Denaro28,14 x 1000
Lettera28,18 x 1000
Min-Max giorno27,69 - 28,19
Intervallo di 52 settimane25,92 - 36,48
Volume1.775.551
Media Volume2.724.383
Capitalizzazione16,824B
Beta (5 anni mensile)0,45
Rapporto PE (ttm)11,13
EPS (ttm)2,53
Prossima data utili09 mag 2024
Rendimento e dividendo (futuro)0,84 (3,01%)
Data ex dividendo16 mag 2024
Stima target 1A45,50
  • GlobeNewswire

    Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

    NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference

  • GlobeNewswire

    Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

    NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenur

  • GlobeNewswire

    Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

    • Proceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa revenue. “This transaction reflects the significant value of Skytrofa. We